Who is sponsoring NCT04547114?

NCT04547114 is sponsored by Klinikum Bayreuth GmbH.

What drugs are being tested in NCT04547114?

Interventions in NCT04547114: Multicapillary column coupled ion mobility spectrometry.

What condition does NCT04547114 study?

NCT04547114 studies SARS-CoV-2 Infection.

Is NCT04547114 still recruiting?

NCT04547114 is currently status unknown. Last updated 14 September 2020.

Last reviewed 2020-09-14 · How we verify

NCT04547114

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Breath Analysis for SARS-CoV-2 in Infected and Healthy Subjects

Status unknown Last updated 14 September 2020

What this trial tests

trial testing Multicapillary column coupled ion mobility spectrometry in SARS-CoV-2 Infection in 200 participants. Status unknown.

Timeline

14 September 2020

Primary endpoint
31 December 2020

30 April 2021

Quick facts

Lead sponsor	Klinikum Bayreuth GmbH
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	14 September 2020
Primary completion	31 December 2020
Estimated completion	30 April 2021
Sites	1 location across Germany

Drugs / interventions tested

Multicapillary column coupled ion mobility spectrometry

Conditions studied

SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →

Sponsor

Klinikum Bayreuth GmbH

Who can join

18 and older, any sex, with SARS-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recently published studies could demonstrate that detection of specific biomarkers in breath could be applied for the diagnosis of SARS-CoV-2.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for SARS-CoV-2 Infection

Currently open trials in the same condition.

NCT07079670 — Safety and Immunogenicity of NVX-CoV2705 · Phase 3 · active not recruiting
NCT05697068 — Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos · NA · active not recruiting
NCT05172011 — Understanding the Long-term Impact of COVID on Children and Families · active not recruiting
NCT05141058 — T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients · Phase 1 · recruiting
NCT05046470 — SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study · active not recruiting

Other Klinikum Bayreuth GmbH trials

Trials by the same sponsor.

NCT04282135 — Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04547114 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Klinikum Bayreuth GmbH
Last refreshed: 14 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04547114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing